

## Instructions for Authors 2015

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear inline in the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear inline in the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions to authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2014): 65%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

# CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iarjournals.org](http://www.iarjournals.org)

## A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

## Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor- $\beta$ 1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (*Loma Linda, CA; Winston-Salem, NC, USA*)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (*Omaha, NE; Ocala, FL, USA*)

Organ-specific Responses of Total Body Irradiated Doxycycline-inducible Manganese Superoxide Dismutase Tet/Tet Mice. B.H. RHIEU, A. SHINDE, M.W. EPPERLY, T. DIXON, H. WANG, R. CHAILLET, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effect of GPIIb/IIIa Inhibition with Eptifibatid or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (*Heidelberg; Tuebingen; Kirchheim; Solingen, Germany*)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems *In Vivo*. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (*Syracuse, NY, USA*)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (*Columbus, OH; San Juan Capistrano, CA, USA*)

Efficacy and Side Effects of a Semi-individualized Chinese Herb Mixture "Tiáo Gēng Tāng" for Menopausal Syndrome in China. M. JIA, L. KLUWE, H.-C. LIU, Q.-J. TANG, L. LIU, Z.-Z. WANG, L.-X. TIAN, L. ZHAO, Y.-C. CHEN, R.E. FRIEDRICH, Z.-J. SUN, L.-W. XU (*Shanghai, PR China; Hamburg, Germany*)

Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (*Jackson, MS, USA*)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKKESFELDT, J. ROSENBERG, I. GÖGENUR (*Køge; Copenhagen; Herlev, Denmark*)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada*)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (*Tokyo; Saitama; Aichi, Japan*)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUJIKAWA, A. TANAKA (*Kobe; Osaka; Suita; Kainan, Japan*)

CAG-repeats in Androgen Receptor Gene Relate with Plasma Androgens Levels in the Bouvier Des Flandres. H. L' EPLATTENIER, E. TESKE, F. VAN SLUIJS, J.A. MOL (*Utrecht, Netherlands*)

Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R.E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS (*Hamburg; Aachen, Germany*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# Subscription Order Form 2016

- Please enter a Subscription to ANTICANCER RESEARCH Volume 36 (2016).  
Annual subscription rates (2016): Institutional, US\$ 1898.00 online, US\$ 2277.00 online & print; Personal, US\$ 897.00 online; US\$ 1277.00 online & print; Prices include rapid delivery and insurance.  
2016 online subscriptions include free online access to vol. 24 (2004) - 35 (2015).
- Please send me the following previous volumes (1-35) at 50% discount on the above rates.
- Please invoice.
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....

Tel: .....

Fax: ..... e-mail: .....

Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: [subscriptions@iiar-anticancer.org](mailto:subscriptions@iiar-anticancer.org)

## Special 2016 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2016 on a basis of priority and availability. Effective from January to December 2016).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 35 years.

- 1981-2015
- 35 volumes
- over 123,000 pages
- over 17,700 original articles
- 870 reviews
- over 80,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:  
ANTICANCER RESEARCH, International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: [subscriptions@iiar-anticancer.org](mailto:subscriptions@iiar-anticancer.org)

## Special Subscription Order Form 2016

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2016 (Volume 36) at the special Author's rate of US\$ 465.00 (print or online).
- Please send me previous Volume No(s) ..... at US\$ 224.00 (print) per volume.
- Please enter my personal combined 2016 subscription to Anticancer Research (Volume 36) and IN VIVO (Volume 30) at US\$ 644.00 (print or online).
- Please send me an invoice.  
Prices include rapid delivery and insurance.

Name and address: .....

Tel-Fax: .....

e-mail: .....

Date and signature: .....

Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer. M. SHIOTA, A. TAKEUCHI, M. SUGIMOTO, E. KASHIWAGI, T. DEJIMA, K. KIYOSHIMA, J. INOKUCHI, K. TATSUGAMI, A. YOKOMIZO ( <i>Fukuoka, Japan</i> ) .....	6925
Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer. G. PAPADAKIS, S. KALAITZIDOU, E. TRIANTAFILLOU, A. DROSOU, K. KAKAVA, N. DOGKAS, T. PAPPAS, V. KALTZIDOU, A. TERTIPI, V. VILLIOTOU, A. PAPPAS ( <i>Athens, Greece</i> ) .....	6933
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. L. MANSO, A.G. PALOMO, R.P. CARRIÓN, J. CASSINELLO, I.G. SANCHO, I.C. LÓPEZ-MUÑIZ, C. OLIER, A. FERNÁNDEZ-ARAMBURO, C. LLORCA, X. GONZÁLEZ, R. LLORENTE, D. TORREGROSA, I. ÁLVAREZ, E. GÁLVE, C. BUENO, I. GARAU, M.J. GARCÍA, S. GONZÁLEZ-SANTIAGO, A.I. BALLESTEROS, E. BLANCO, A. GALÁN, S. GONZÁLEZ, A. PERELLÓ, H. CORTÉS-FUNES, C. GRÁVALOS ( <i>Madrid; León; Guadalajara; Segovia; Toledo; Alicante; Valencia; Huesca; Palma de Mallorca; Ciudad Real; Cáceres; Badajoz; Barcelona, Spain</i> ) .....	6941
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer? F. FANFANI, A. FAGOTTI, A. ERCOLI, V. GALLOTTA, V. CHIANTERA, S. RESTAINO, G. MONTEROSSO, G. SCAMBIA ( <i>Rome; Terni; Padua; Campobasso; Trieste, Italy</i> ) .....	6951
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion. S. WATANABE, A. INOUE, T. NUKIWA, K. KOBAYASHI ( <i>Niigata; Sendai; Tokyo; Hidaka City, Saitama, Japan</i> ) .....	6957
Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma. K. SHIRABE, K. SUGIMACHI, N. HARADA, H. KAYASHIMA, T. MAEDA, E. TSUJITA, R. MINAGAWA, K. KAJIYAMA, S. YOSHIYA, Y. MAEHARA ( <i>Fukuoka; Kitakyushu; Hiroshima; Iizuka, Japan</i> ) .....	6963
Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluorouracil. G.C. CAVALCANTE, N.D.S.D.C. FREITAS, A.M. RIBEIRO-DOS-SANTOS, D.C. DE CARVALHO, E.M. DA SILVA, P.P. DE ASSUMPCÃO, Â. RIBEIRO-DOS-SANTOS, S. SANTOS, N.P.C. DOS SANTOS ( <i>Belém, PA, Brazil</i> ) .....	6971
Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer. A. SPAKS, I. JAUNALKSNE, I. SPAKA, D. CHUDASAMA, A. PIRTNIEKS, D. KRIEVINS ( <i>Middlesex; Cardiff, UK; Riga, Latvia</i> ) .....	6979
Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma. E.J. LEE, S.-H. CHANG, T.Y. LEE, S.Y. YOON, Y.K. CHEON, C.S. SHIM, Y. SO, H.W. CHUNG ( <i>Seoul, Republic of Korea</i> ) .....	6985
Errata .....	6993
Index .....	6995

Comparison of Failure Patterns Between Conventional and Intensity-modulated Radiotherapy for Stage III and IV Head and Neck Squamous Cell Carcinoma. J.H. SONG, B.-K. JEONG, H.-S. CHOI, H. JEONG, M.H. KANG, J.H. KANG, J.P. KIM, J.J. PARK, S.H. WOO, H.S. JANG, B.O. CHOI, K.M. KANG ( <i>Jinju; Seoul, Republic of Korea</i> ) .....	6833
Correlation Between Different ADC Fractions, Cell Count, Ki-67, Total Nucleic Areas and Average Nucleic Areas in Meningothelial Meningiomas. A. SUROV, H. CAYSA, A. WIENKE, R.P. SPIELMANN, E. FIEDLER ( <i>Halle, Germany</i> ) .....	6841
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. F. RECCHIA, G. CANDELORO, M. ROSSELLI, M. BRATTA, V. PASTA, V. D'ORAZI, L.A. FUMAGALLI, S. REA ( <i>Avezzano; Frascati; Rome; Aquila; Lecco, Italy</i> ) .....	6847
Hepatic Resection for Hepatocellular Carcinoma in the Elderly: Selecting Hepatectomy Procedures Based on Patient Age. S. SATO, K. TANAKA, K. NOJIRI, T. KUMAMOTO, R. MORI, K. TANIGUCHI, R. MATSUYAMA, K. TAKEDA, M. UEDA, H. AKIYAMA, M. TAGURI, I. ENDO ( <i>Yokohama, Kanagawa; Ichihara, Chiba, Japan</i> ) .....	6855
Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma. M. KOMATSU, Y. ARAI, K. YABUKI, D. SANO, O. SHIONO, Y. SAKUMA, G. NISHIMURA, M. TAKAHASHI, T. TAGUCHI, N. ORIDATE ( <i>Yokohama, Japan</i> ) .....	6861
Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. R. CHEKEROV, G. KALTENECKER, D. REICHERT, T. GÖHLER, P. KLARE, G. OSKAY-ÖZCELİK, U. SAUER, A. WISCHNIK, U. VEHLING-KAISER, M. BECKER, U. HUTZSCHENREUTER, A. AMMON, E. HEIDRICH-LORSBACH, J. SEHOULI ( <i>Berlin; Karlsruhe; Westerstede; Dresden; Nordhorn; Augsburg; Landshut; Minden; Göttingen; Giessen, Germany</i> ) .....	6869
The Role of Re-resection for Breast Cancer Liver Metastases-a Single Center Experience. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU ( <i>Bucharest, Romania</i> ).....	6877
The Role of Percutaneous Biopsy and Prognostic Factors of Malignancy in Solitary Breast Papilloma: A Retrospective Multicenter Study of 259 Cases. M. LAVAL, R. DELANGLE, A. NDOYE, E. SYLVESTRE, B. LAVIOLLE, V. LAVOUE, J. LEVÊQUE ( <i>Rennes; Tours; Poitiers, France</i> ).....	6881
Undetermined Margins After Colonoscopic Polypectomy for Malignant Polyps: The Need for Radical Resection. E.-J. JUNG, C.-G. RYU, J.H. PAIK, D.-Y. HWANG ( <i>Seoul, Republic of Korea</i> ).....	6887
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. L. DECOSTER, I.V. BROEK, B. NEYNS, F. MAJOIS, J.F. BAURAIN, S. ROTTEY, A. RORIVE, E. ANCKAERT, J. DE MEY, S. DE BRAKELEER, J. DE GRÈVE ( <i>Brussels; Sint Niklaas; Haine Saint Paul; Gent; Liège, Belgium</i> ).....	6893
Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. M.J. ABRAMS, K.E. HUBER, J.P.S. KNISELY, B.W. CHANG, S.M. RUSSO, M.W. SAIF ( <i>Boston, MA; New York, NY; Torrance, CA; Cleveland, OH, USA</i> ) .....	6901
One-stage Procedure for Concomitant Abdominal Aortic Aneurysm and Gastric Cancer. T. MATSUMOTO, D. MATSUDA, K. HONMA, Y. AOYAGI, J. OKADOME, K. MORISAKI, S. TANAKA, H. SAEKI, E. OKI, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	6909
Long-term Survivors After Liver Resection for Breast Cancer Liver Metastases. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU ( <i>Bucharest, Romania</i> ).....	6913
Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU ( <i>Bucharest, Romania</i> ) .....	6919



A Multidisciplinary Approach for Advanced Gastric Cancer with Paraaortic Lymph Node Metastasis. Y. FUJIWARA, T. OMORI, K. DEMURA, H. MIYATA, K. SUGIMURA, M. OHUE, S. KOBAYASHI, H. TAKAHASHI, Y. DOKI, M. YANO ( <i>Osaka, Japan</i> ) .....	6739
Adequate Margins to Prevent Local Re-recurrence of Rectal Cancer: Viewpoint of Pathological Findings. K. KOMORI, K. KIMURA, T. KINOSHITA, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, S. NATSUME, J. KAWAKAMI, Y. IWATA, M. TSUTSUYAMA, I. SHIGEYOSHI, T. AKAZAWA, D. HAYASHI, Y. SHIMIZU ( <i>Nagoya, Aichi, Japan</i> ) .....	6747
Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. V. BARAK, V. LEIBOVICI, T. PERETZ, I. KALICHMAN, M. LOTEM, S. MERIMS ( <i>Jerusalem, Israel</i> ) ...	6755
Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer. S.A. THOMAS, N. TOMEH, S. THEARD ( <i>Suwanee, GA, USA</i> ) .....	6761
Predictors of Gastric Neoplasia in Cases Negative for <i>Helicobacter pylori</i> Antibody and with Normal Pepsinogen. H. KISHIKAWA, K. KIMURA, A. ITO, K. ARAHATA, S. TAKARABE, S. KAIDA, J. MIYAUCHI, S. MIURA, J. NISHIDA ( <i>Chiba; Saitama, Japan</i> ) .....	6765
Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts. L. ALBERTS, S.Y. EL SHAROUNI, F.N. HOFMAN, B.P. VAN PUTTE, E. TROMP, M. VAN VULPEN, E.A. KASTELIJN, F.M.N.H. SCHRAMMEL ( <i>Nieuwegein; Utrecht, the Netherlands</i> ) .....	6773
D-dimer Level Changes During Systemic Chemotherapy Can Predict Prognosis of High-grade Musculoskeletal Sarcoma Patients. T. MORII, T. TAJIMA, T. AOYAGI, S. ICHIMURA ( <i>Tokyo, Japan</i> )....	6781
Detection of Bone Metastases Using <sup>11</sup> C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence. C. SPICK, S.H. POLANEC, M. MITTERHAUSER, W. WADSAK, P. ANNER, B. REITERITS, A.R. HAUG, M. HACKER, M. BEHESHTI, G. KARANIKAS ( <i>Vienna; Linz, Austria</i> ) .....	6787
Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. L. DZIGGEL, M. DAHLKE, S. JANSSEN, D. HORNUNG, O. BLANCK, M.T. KHOA, S.E. SCHILD, D. RADES ( <i>Lübeck; Hannover; Hamburg; Güstrow, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i> ) .....	6793
Cancer Incidence in Patients with Atypical Endometrial Hyperplasia Managed by Primary Hysterectomy or Fertility-sparing Treatment. C. GONTHIER, B. PIEL, C. TOUBOUL, F. WALKER, A. CORTEZ, D. LUTON, E. DARAÏ, M. KOSKAS ( <i>Paris, France</i> ) .....	6799
Radiosurgery Using Tomotherapy for Patients with Brain Oligo-metastasis: A Retrospective Analysis on Feasibility and Tolerance. A. BRUNI, S. GAITO, A. CIARMATORI, B. LANFRANCHI, E. MAZZEO, N. MAFFEI, P. GIACOBAZZI, E. TURCO, G. GUIDI, F. BERTONI ( <i>Modena, Italy</i> ) .....	6805
Ipsilateral Sphenoid Wing Dysplasia, Orbital Plexiform Neurofibroma and Fronto-Parietal Dermal Cylindroma in a Patient with Segmental Neurofibromatosis. R.E. FRIEDRICH, C. HAGEL, V.-F. MAUTNER ( <i>Hamburg, Germany</i> ) .....	6813
Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. T. ASO, H. UOZAKI, S. MORITA, A. KUMAGAI, M. WATANABE ( <i>Tokyo, Japan</i> ) .....	6819
Retrograde Jejunojunal Intussusception After Gastrectomy: Report of Four Cases. S. YOSHIYA, T. NAKANOKO, T. KOGA, S. INOKUCHI, K. HIROSE, Y. HIRAYAMA, K. TAKETANI, R. YOSHIDA, R. MINAGAWA, M. KAI, K. KAJIYAMA, Y. MAEHARA ( <i>Iizuka; Higashiku, Fukuoka, Japan</i> ) .....	6829

2-Deoxy-D-glucose Sensitizes Cancer Cells to Barasertib and Everolimus by ROS-independent Mechanism(s). Z. ZHELEV, D. IVANOVA, I. AOKI, T. SAGA, R. BAKALOVA ( <i>Stara Zagora; Sofia, Bulgaria; Chiba, Japan</i> ) .....	6623
Molecular Pathogenesis of Human Papillomavirus Type 16 in Tonsillar Squamous Cell Carcinoma. S. HASSANI, A. CASTILLO, J.-I. OHORI, M. HIGASHI, Y. KURONO, S. AKIBA, C. KORIYAMA ( <i>Kagoshima, Japan; Cali, Colombia</i> ) .....	6633
Fumarate Hydratase-deficient Cell Line NCCFH1 as a New <i>In Vitro</i> Model of Hereditary Papillary Renal Cell Carcinoma Type 2. V. PERRIER-TRUDOVA, B.W. HUIMIN, S. KONGPETCH, D. HUANG, P. ONG, A. LE FORMAL, S.L. POON, E.Y. SIEW, S.S. MYINT, S. GAD, B. GARDIE, S. COUVÉ, Y.M. FOONG, Y. CHOUDHURY, J. POH, C.K. ONG, C.K. TOH, A. OOI, S. RICHARD, M.-H. TAN, B.T. TEH ( <i>Villejuif; Nantes; Paris, France; Singapore, Republic of Singapore; Arizona, AZ, USA</i> ).....	6639
Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model. K. SCHMIDT, C. MOSER, C. HELLERBRAND, D. ZIEKER, C. WAGNER, J. REDEKOPF, H.J. SCHLITT, E.K. GEISSLER, S.A. LANG ( <i>Regensburg; Tuebingen, Germany</i> ) .....	6655
<i>HER2</i> Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. R. WATROWSKI, D.C. CASTILLO-TONG, A. WOLF, E. SCHUSTER, M.B. FISCHER, P. SPEISER, R. ZEILLINGER ( <i>Freiburg, Germany; Vienna, Austria</i> ) .....	6667
Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines. K. MIZUTANI, M. TOMODA, Y. OHNO, H. HAYASHI, Y. FUJITA, K. KAWAKAMI, K. KAMEYAMA, T. KATO, T. SUGIYAMA, Y. ITOH, M. ITO, T. DEGUCHI ( <i>Gifu; Tokyo, Japan</i> ) .....	6671
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line. K. HAGIWARA, T. TOKUNAGA, H. IIDA, H. NAGAI ( <i>Nagoya, Japan</i> ).....	6679
Amentoflavone Induces Anti-angiogenic and Anti-metastatic Effects Through Suppression of NF- $\kappa$ B Activation in MCF-7 cells. J.-H. CHEN, W.-L. CHEN, Y.-C. LIU ( <i>Taipei; Yilan, Taiwan, ROC</i> ) .....	6685
ABSTRACTS OF THE INTERNATIONAL CONFERENCE ON ADVANCES IN HEMATOLOGY AND ONCOLOGY, 28-29 August, 2015 ( <i>Coeur d'Alene, ID, USA</i> ) .....	6695

### *Clinical Studies*

Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910. K. YAMADA, H. SAITO, T. KONDO, S. MURAKAMI, N. MASUDA, M. YAMAMOTO, S. IGAWA, K. KATONO, Y. TAKIGUCHI, S. IWASAWA, R. KURIMOTO, H. OKAMOTO, T. SHIMOKAWA, Y. HOSOMI, Y. TAKAGI, K. KISHI, M. OHBA, F. OSHITA, K. WATANABE ( <i>Yokohama; Sagami-hara; Chiba; Yokohama; Tokyo; Matsuda-machi; Kanagawa, Japan</i> ).....	6705
Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. S. BOUSSIOS, A. ATTYGALLE, S. HAZELL, M. MOSCHETTA, J. MCLACHLAN, A. OKINES, S. BANERJEE ( <i>London, UK</i> ) .....	6713
Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study. C.B. TEMPFER, G.A. REZNICZEK, P. ENDE, W. SOLASS, M.-A. REYMOND ( <i>Bochum; Hannover, Germany</i> ) .....	6723
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. Z.G. ZIMLING, E. SANTONI-RUGIU, C. BECH, J.B. SØRENSEN ( <i>Copenhagen, Denmark</i> ) .....	6731

Vascular Innervation in Benign Neurofibromas of Patients with Neurofibromatosis Type 1. R.E. FRIEDRICH, C.-A. BEHRENDT, M. GLATZEL, C. HAGEL ( <i>Hamburg, Germany</i> ) .....	6509
Cytological and Immunocytological Monitoring of Oropharyngeal Dysplasia and Squamous Cell Carcinomas. M. ANDRATSCHKE, S. SCHMITZ, H. HAGEDORN, A. NERLICH ( <i>Munich; Lübeck, Germany</i> ) .....	6517
Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane. O. FERICIAN, A.M. CIMPEAN, S. AVRAM, M. RAICA ( <i>Timisoara, Romania</i> ) .....	6521
Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells. S.H. KIM, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, H.J. YOO, S.J. LEE ( <i>Chuncheon, Republic of Korea</i> ) .....	6529
Tumour Progression and Spontaneous Regression in the Lewis Rat Sarcoma Model. J. KOVALSKÁ, R. MISHRA, L. JEBAVÝ, P. MAKOVICKÝ, J. JANDA, D. PLÁNSKÁ, M. ČERVINKOVÁ, V. HORÁK ( <i>Liběchov; Prague, Czech Republic</i> ) .....	6539
Pattern of Melanotransferrin Expression in Human Colorectal Tissues: An Immunohistochemical Study on Potential Clinical Application. K. DUŚ-SZACHNIEWICZ, P. OSTASIEWICZ, M. WOŹNIAK, P. KOŁODZIEJ, J.R. WIŚNIEWSKI, P. ZIÓŁKOWSKI ( <i>Wrocław, Poland; Martinsried, Germany</i> ) .....	6551
Phosphatidylinositol Derivatives Induce Gastric Cancer Cell Apoptosis by Accumulating AIF and AMID in the Nucleus. M. OHYAMA, A. TSUCHIYA, Y. KAKU, T. KANNO, T. SHIMIZU, A. TANAKA, T. NISHIZAKI ( <i>Nishinomiya; Kobe, Japan</i> ) .....	6563
Bioluminescence Imaging of Adoptively Transferred Lymphocytes During Allogeneic Tumor Rejection. J. JURŠĚNAITĚ, I. GIRKONTAITĚ, M. MAURICAS, R. EIDUKEVIČIUS, A. ŠIAURYS, D. CHARACIEJUS ( <i>Vilnius, Lithuania</i> ) .....	6573
Microarray Analysis of Gene Expression at the Tumor Front of Colon Cancer. T. KOBAYASHI, T. MASAKI, E. NOZAKI, M. SUGIYAMA, F. NAGASHIMA, J. FURUSE, H. ONISHI, T. WATANABE, Y. OHKURA ( <i>Tokyo, Japan</i> ) .....	6577
Potential of Acute Promyelocytic Leukemia Cell Differentiation and Prevention of Leukemia Development in Mice by Oleanolic Acid. R.D.S. RAWENDRA, P.-Y. LIN, C.-D. CHANG, J.-L. HSU, T.-C. HUANG, W.-L. SHIH ( <i>Pingtung, Taiwan, ROC</i> ) .....	6583
Clinical Significance of Expression of Nephroblastoma Overexpressed (NOV) in Patients with Colorectal Cancer. M. UEDA, T. IGUCHI, H. KOMATSU, S. KIDOGAMI, Q. HU, K. SATO, Y. OGAWA, S. NAMBARA, T. SAITO, S. SAKIMURA, H. HIRATA, R. UCHI, Y. SHINDEN, H. EGUCHI, S. ITO, T. MASUDA, H. YAMAMOTO, Y. DOKI, M. MORI, K. MIMORI ( <i>Beppu; Suita, Japan</i> ) .....	6591
CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer. S. KAZAMA, J. KISHIKAWA, K. YASUDA, K. OTANI, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, H. NOZAWA, H. YAMAGUCHI, S. ISHIHARA, E. SUNAMI, T. WATANABE ( <i>Tokyo, Japan</i> ) .....	6599
GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells. H. SAKAKI, M. OKADA, K. KURAMOTO, H. TAKEDA, H. WATARAI, S. SUZUKI, S. SEINO, M. SEINO, T. OHTA, S. NAGASE, H. KURACHI, C. KITANAKA ( <i>Yamagata; Osaka, Japan</i> ) .....	6607
Up-regulation of <i>PER3</i> Expression Is Correlated with Better Clinical Outcome in Acute Leukemia. M.-Y. YANG, P.-M. LIN, H.-H. HSIAO, J.-F. HSU, H.-Y. LIN, C.-M. HSU, I.-Y. CHEN, S.-W. SU, Y.-C. LIU, S.-F. LIN ( <i>Tao-Yuan; Kaohsiung, Taiwan, ROC</i> ) .....	6615

Enhanced Systemic Bioavailability of Curcumin Through Transmucosal Administration of a Novel Microgranular Formulation. B. LATIMER, O. EKSHYYAN, N. NATHAN, T. MOORE-MEDLIN, X. RONG, X. MA, A. KHANDELWAL, H.T. CHRISTY, F. ABREO, G. MCCLURE, J.A. VANCHIERE, G. CALDITO, T. DUGAS, K. MCMARTIN, T. LIAN, V. MEHTA, C.-A.O. NATHAN ( <i>Shreveport; Baton Rouge, LA, USA</i> ).....	6411
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. T. YEROKUN, L.L. WINFIELD ( <i>Atlanta, GA, USA</i> ) .....	6419
Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen. R.G. STAUFFER, M. MOHAMMAD, A.T.K. SINGH ( <i>Kenosha, WI, USA</i> ) .....	6425
Establishment of a Novel <i>In Vitro</i> Model for Predicting Incidence and Severity of Microtubule-targeting Agent-induced Peripheral Neuropathy. Y. SAWAGUCHI, S. UENO, Y. NISHIYAMA, R. YAMAZAKI, T. MATSUZAKI ( <i>Tokyo, Japan</i> ) .....	6431
Evidence of <sup>18</sup> F-FCH Uptake in Human T98G Glioblastoma Cells. F.E. BURONI, F. PASI, M.G. PERSICO, L. LODOLA, C. APRILE, R. NANO ( <i>Pavia, Italy</i> ) .....	6439
Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors. C. HOLZMANN, D.N. MARKOWSKI, I. VON LEFFERN, T. LÖNING, J. BULLERDIEK ( <i>Rostock; Bremen; Hamburg, Germany</i> ).....	6445
Comparison of Methods to Identify Lymphatic and Blood Vessel Invasion and their Prognostic Value in Patients with Primary Operable Colorectal Cancer. H.C. VAN WYK, A.K. FOULIS, C.S. ROXBURGH, C. ORANGE, P.G. HORGAN, D.C. MCMILLAN ( <i>Glasgow, UK</i> ).....	6457
Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy. S. RAATIKAINEN, S. AAALTOMAA, V. KÄRJÄ, Y. SOINI ( <i>Kuopio, Finland</i> ).....	6465
Ferredoxin Reductase Is Useful for Predicting the Effect of Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma. H. OKUMURA, Y. UCHIKADO, I. OMOTO, M. MOTOMURA, Y. KITA, K. SASAKI, M. NODA, T. ARIGAMI, Y. UENOSONO, K. BABA, S. MORI, Y. KIJIMA, A. NAKAJO, H. KURAHARA, K. MAEMURA, M. SAKODA, T. OWAKI, S. ISHIGAMI, S. NATSUGOE ( <i>Kagoshima, Japan</i> ) .....	6471
Down-regulation of HDGF Inhibits the Growth of Hepatocellular Carcinoma Cells <i>In Vitro</i> and <i>In Vivo</i> . H. ENOMOTO, H. NAKAMURA, W. LIU, Y. IWATA, H. NISHIKAWA, R. TAKATA, K. YOH, K. HASEGAWA, A. ISHII, T. TAKASHIMA, Y. SAKAI, N. AIZAWA, N. IKEDA, H. IJIMA, S. NISHIGUCHI ( <i>Nishinomiya, Hyogo; Osaka, Japan; Guangdong, PR China</i> ) .....	6475
A Biomimicking Tumor Tissue Model Using Hepatocellular Carcinoma Cell Sheet in a Collagen Sandwich System. Y. IWASE, M. NAKAYAMA, M. YAMATO, T. OKANO ( <i>Tokyo, Japan</i> ).....	6481
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. M.-W. POON, J.T.F. ZHUANG, S.T.S. WONG, S. SUN, X.-Q. ZHANG, G.K.K. LEUNG ( <i>Hong Kong, ROC</i> ) .....	6487
Comparative Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE. F. PASCALE, L. BEDOJET, M. BAYLATRY, J. NAMUR, A. LAURENT ( <i>Jouy-en-Josas; Paris, France</i> ) .....	6497
Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors. O. KADIOGLU, J. SERLY, E.-J. SEO, I. VINCZE, C. SOMLAI, M.E.M. SAEED, J. MOLNÁR, T. EFFERTH ( <i>Mainz, Germany; Szeged, Hungary</i> ).....	6505